Document:

Exhibit 10.1

 

STOCK SURRENDER
AGREEMENT

 

This
STOCK SURRENDER AGREEMENT (the “Agreement”) dated as of May 11, 2015, by and among the individuals listed on
Schedule A (each a “Shareholder” and collectively, “Shareholders”) and VAPE Holdings, Inc.
(the “Company”).

 

W I T N
E S S E T H:

 

WHEREAS,
the Shareholders are current officers, directors and/or employees of the Company;

 

WHEREAS,
on January 6, 2015 and January 27, 2015, as applicable, the Shareholders were transferred an aggregate of 440,625 shares of common
stock, par value $0.00001 per share (the “Common Stock”) pursuant to a settlement agreement with certain other shareholders
of the Company;

 

WHEREAS,
each Shareholder desires to surrender his legal right, title and interest in the number of shares of Common Stock set forth opposite
his name on Schedule A hereto, which shares total 440,625 (the “Shares”) to the Company which will be held
by the Company as treasury stock;

          

NOW,
THEREFORE, in consideration of the promises and mutual covenants, agreements, representations and warranties herein contained,
the parties hereto agree as follows:

 

1. Surrender
of Shares. Subject to the terms and conditions of this Agreement, as of the date first above written, Shareholders hereby
surrender all legal right, title and interest in the Shares to the Company to be held by the Company as treasury stock. The Shareholders
shall receive no consideration for the surrendered Shares.

 

2. Further
Assurances. After the date hereof, Shareholders agree to take any and all actions necessary to surrender the Shares to the
Company.

 

3. Acknowledgements.
The parties hereto acknowledge and agree that the intent and purpose of the transaction contemplated by this Agreement is not
to hinder or defraud any creditor of Shareholders.

 

4. Entire
Agreement: Amendments. This Agreement contains, and is intended as, a complete statement of all the terms of the arrangements
between the parties with respect to the matters provided for and supersedes any and all prior agreements, arrangements and understandings
between the parties with respect to the matters provided for herein. No alteration, waiver, amendment, change or supplement hereto
shall be binding or effective unless the same is set forth in writing, signed by the parties hereto or a duly authorized representative
thereof.

 

5. Notices.
Any notices required or permitted to be given under this Agreement shall be in writing, signed by the party giving such notice
and shall be deemed duly given when sent by registered or certified mail return receipt requested, to the other parties hereto
at such parties address set forth on the signature page hereto or at such other address as such parties shall designate by similar
notice to the other parties. 

 

6. Governing
Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California,
without giving effect to principles of conflicts of law or choice of law. Each Shareholders and the Company hereby agree that
the state and federal courts located in Los Angeles, California, shall have exclusive jurisdiction and venue over all actions
relating to this Agreement.

 

[Signatures
on following page]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have hereunto executed this Agreement on the day and year first above written.

 

	 	VAPE
    HOLDINGS, INC.     
	 	 
	 	By:   	 
	 	Name:  	Kyle
    Tracey
	 	Title:  	CEO
	 	 	 
	 	SHAREHOLDERS
	 	 
	 	 
	 	Kyle
    Tracey  
	 	 
	 	 
	 	Benjamin
    Beaulieu   
	 	 
	 	 
	 	Joe
    Andreae   

 

    	 

    	 

    

 

Schedule A

 

	Shareholder	 	Number of Shares to be Transferred to the Company	 
	Kyle Tracey	 	 	100,000	 
	Benjamin Beaulieu	 	 	170,312	 
	Joe Andreae	 	 	170,313	 
	Total	 	 	440,625Exhibit 10.2

 

OPTION SURRENDER
AGREEMENT

 

	TO:	VAPE HOLDINGS, INC. (THE “COMPANY”)

 

	RE:	SURRENDER OF OPTIONS

 

The
undersigned holder of non-statutory stock options (the “Company Options”) to acquire shares of common
stock of the Company, par value $0.00001, granted pursuant to the 2014 Incentive and Nonstatutory Stock Option Plan (the “Plan”),
agrees to surrender each Company Option set forth on Exhibit A hereto (the “Surrendered Options”). The
undersigned is permitted to surrender, for no consideration, Company Options pursuant to Section 10 of their Nonstatutory Stock
Option Agreement (the “Option Agreement”)

 

The
undersigned has determined to surrender the Surrendered Options, each of which has an exercise price substantially greater than
the current trading price of the Company’s common stock, in order to assist the Company in attracting and retaining talented
executive and employees in the future.

 

Therefore,
without requiring any further action on the part of the undersigned, and notwithstanding any terms of the Option Agreement to the
contrary, the undersigned hereby irrevocably elects to surrender the Surrendered Options immediately upon the execution of this
agreement by the undersigned.

 

In
connection with the surrender of the Surrendered Options, the undersigned represents and warrants to the Company that (a) he
or she is the beneficial and registered owner of the Surrendered Options, which are free and clear of all liens, charges, encumbrances
and any other rights of others; (b) he or she has good and sufficient power, authority and right to enter into and deliver
this agreement and to transfer the legal and beneficial title and ownership of the Surrendered Options to the Company, free and
clear of all liens, charges and encumbrances; (c) he or she has duly executed and delivered this agreement and it constitutes
a valid and legally binding obligation on him or her, enforceable against him or her in accordance with its terms; (d) there
is no contract, option or any other right of another binding upon or which at any time in the future may become binding upon him
or her to sell, transfer, assign, pledge, charge, mortgage or in any other way dispose of or encumber any of the Surrendered Options
other than pursuant to the terms of this agreement; and (e) the undersigned has not been promised, nor has he or she received
nor will he or she receive, any cash or any grants of equity awards relating to shares of Company common stock in exchange or consideration
for the surrender of the Surrendered Options.

 

In
the event of a conflict between the terms of this agreement and the Plan or the applicable Option Agreement, the provisions of
this agreement shall control.

 

The
undersigned acknowledges that he or she has read this agreement, understands it and voluntarily accepts its terms. The undersigned
further acknowledges that this agreement is executed voluntarily and without any duress or undue influence on the part of or on
behalf of the Company.

 

This
agreement shall be governed and construed in accordance with the laws of the State of California, without regard to conflicts of
laws thereof. This agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the
signatures affixed thereto were upon the same instrument.

 

This
agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors, permitted assigns
and legal representatives.

 

[Signatures
on following page]

 

    	 

    	 

    

 

DATED as
of the ___day of May, 2015.

 

	 	 	 
	 	[Name of Option Holder]	 

 

Accepted by the Company on this
___day of May, 2015.

 

	 	VAPE HOLDINGS, INC.
	 	 	 
	 	By:	 
	 	 	Kyle Tracey,
	 	 	Chief Executive Officer

 

    	 

    	 

    

 

EXHIBIT A

 

SURRENDERED
OPTIONSEX-10.3

 Exhibit 10.3 
  

 
 February 4, 2015 
 Adam
Woodrow 
 1675 Stephens Drive 
 Wayne, PA 19087 

Re:  Amended and Restated Employment Agreement 

Dear Adam: 
 On behalf of Paratek Pharmaceuticals, Inc.
(“Paratek” or the “Company”) I am pleased to offer you continued employment under the terms of this Amended and Restated Employment Agreement (the “Agreement”). In this Agreement, you and the
Company hereby amend, supersede, and restate in its entirety that certain offer letter agreement between the Company and you dated August 28, 2014 (the “Employment Agreement”). 

Employment Position and Duties 
 You will be employed in
the position of Chief Commercialization Officer (“CCO”). In this role, you will be expected to prepare and implement the commercialization strategy for each of the Company’s late stage development candidates, with the primary
focus being on omadacycline and, to the extent necessary, sarecycline. As CCO, you will also be expected to support any and all partnering efforts associated with the Company’s late stage development compounds. In addition you will be expected
to perform other customary duties of your position, duties specified in the Bylaws of the Company, and as may be required by the Company’s Board of Directors (the “Board”). You will report to the Chief Executive Officer. 

You will work at the Company’s Philadelphia area facility. During your employment with the Company, you will devote your full-time best efforts and
business time and attention to the business of the Company. As an exempt salaried employee, you will be expected to be available and working during the Company’s regular business hours, and such additional time as appropriate to manage your
responsibilities. The Company reserves the right to reasonably require you to perform your duties at places other than its Philadelphia area facility from time to time, and to require reasonable business travel, including international travel, at
the Company’s expense. 
 Your employment relationship with the Company will also be governed by the general employment policies and practices of the
Company, except that if the terms of this Agreement conflict, this Agreement will control. The Company reserves the right to change your position, duties, reporting relationship, and work location, from time to time in its discretion. 

Base Salary 
 You will earn a salary at the rate of
$26,666.67 per month ($320,000 annualized), less payroll deductions and withholdings (“Base Salary”), payable on the Company’s regular payroll schedule. The Base Salary will be reviewed on an annual or more frequent basis by
the Board (or any authorized committee thereof), and is subject to change in the discretion of the Board (or any authorized committee thereof). 

 Adam Woodrow 

February 4, 2015 
  Page
 2
 
  

 Discretionary Performance Bonus 

Starting with calendar year 2015, you will be eligible to earn a discretionary performance bonus of up to thirty percent (30%) of your Base Salary,
subject to applicable payroll deductions and withholdings (“Bonus”), based upon the Board’s assessment of your performance, and the Company’s attainment of written targeted goals as determined by the Board in its sole
discretion. Following the close of each calendar year, the Board will determine in its discretion whether you have earned a Bonus, and the amount of any Bonus. No amount of the Bonus is guaranteed. You will be eligible to earn a Bonus for any full
calendar year provided that you are employed by the Company as of December 31. The Bonus, if earned, will be paid no later than March 15 of the calendar year after the year to which it relates. 

Employee Benefits 
 As a regular employee, you will be
eligible to participate in the Company’s standard employee benefits, pursuant to the terms and conditions of the benefit plans and applicable policies, and for any additional benefits provided to the Company’s executive employees
generally. You will also be eligible to accrue paid vacation in accordance with the terms of the Company’s vacation policy. The Company may change employee benefits from time to time in its discretion. Details about these benefits are provided
in the employee handbook and Summary Plan Descriptions, available for your review. 
 Business Expenses 

The Company will pay or reimburse you for all reasonable business expenses incurred or paid by you in the performance of your duties and responsibilities for
the Company, subject to such reasonable substantiation and documentation as may be required by the Company, and subject to any maximum annual limit and other restrictions on or policies governing such expenses as set by the Company from time to
time. 
 Equity Compensation 
 You have been granted
options (the “Options”), under the Transcept Pharmaceuticals, Inc. 2006 Incentive Award Plan (the “2006 Plan”), to purchase 125,391 shares of the Company’s Common Stock, at fair market value as determined by
the Board as of the date of grant. The Options will be governed in full by the terms and conditions of the 2006 Plan and your individual grant agreement; provided, however, the Options shall vest, subject to your continued service with the Company
(as defined in the 2006 Plan), in three equal tranches of 41,797 Options shares each. The first tranche of Options shares shall vest monthly in equal installments over a forty-eight (48)-month period commencing on January 1, 2015, and the other
two tranches shall vest in part based on performance milestones, as specified by the Board. 
 You have been granted Restricted Stock Units
(“RSUs”) under the 2006 Plan, for 35,000 shares of Common Stock of the Company. The RSUs will be governed in full by the terms and conditions of the 2006 Plan and your individual Restricted Stock Unit Award Grant Notice and
Restricted Stock Unit Award Agreement; provided, however, subject to your continued service with the Company as defined in the 2006 Plan, the RSUs shall vest and shares of Common Stock shall be issuable upon the three (3)-year anniversary of the
grant date. 

 Adam Woodrow 

February 4, 2015 
  Page
 3
 
  

 At-Will Employment Relationship 

You may terminate your employment with the Company at any time, with or without Good Reason, and with or without advance notice, and for any reason whatsoever
simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without Cause, and with or without advance notice. Your employment at-will status can only be modified in a written agreement approved by the
Board and signed by you and a duly authorized Member of the Board. 
 Payments upon Termination other than without Cause or with Good Reason 

Upon termination of your employment for any reason other than by the Company without Cause or by you with Good Reason, you shall be paid all accrued but unpaid
Base Salary, any earned but unpaid bonus, reimbursement for business expenses incurred by you but not yet paid to you as of the date your employment terminates, and all accrued but unused vacation (collectively, the “Accrued
Payments”). Your Options shall terminate, as to all unvested shares, as of your termination date. 
 Termination without Cause or with Good
Reason 
 Upon termination of your employment at any time by the Company without Cause or by you with Good Reason, each as defined below, you will
receive the Accrued Payments. In addition, subject to your fulfillment of the Release Obligation, as defined below, you will be eligible to receive cash severance equal to twelve (12) months of Base Salary following the termination date,
subject to payroll withholding and deduction (“Severance Payments”), and paid according to the Company’s regular payroll procedures. Payment of Severance Payments shall commence on the sixtieth (60th) day following your employment termination, which initial payment shall include a lump sum payment equal to the aggregate semi-monthly installments that would otherwise have been due during the
period between the termination date and the sixtieth (60th) day, but for the sixty (60)-day delay in this provision. Thereafter, the remaining installments shall be paid on the Company’s
regular paydays. 
 Definitions 
 For purposes of this
Agreement, the following definitions shall apply: 
 1. “Cause” shall mean the occurrence of any of the following
events: (a) your commission of any felony or any crime involving fraud, embezzlement, dishonesty or moral turpitude under the laws of the United States or any state thereof; (b) your attempted commission of, or participation
in, a fraud, embezzlement or act of dishonesty against the Company or a Company affiliate; (c) your intentional, material violation of any contract or agreement between you and the Company or a Company affiliate or of any statutory duty
owed to the Company or a Company affiliate; (d) your unauthorized use or disclosure of the Company’s or a Company affiliate’s confidential information or trade secrets; (e) your refusal or failure to satisfactorily
perform any duties required of you, if such duties are consistent with duties customary for your position, which continues after a period of thirty (30) days following your receipt of notice from the Company that it deems such conduct Cause for
termination of your employment hereunder; or (f) your gross misconduct. 
 2. “Good Reason” shall exist
for resignation from employment with the Company if any of the following actions are taken by the Company without your prior consent: (a) a material reduction in your Base Salary or Bonus target percentage of Base Salary, unless the
salaries of 

 Adam Woodrow 

February 4, 2015 
  Page
 4
 
  

 
other executive officers of the Company are correspondingly reduced; or (b) a relocation of your principal place of employment to a place that increases your one-way commute by more
than thirty-five (35) miles as compared to your then-current principal place of employment immediately prior to such relocation. In order for you to resign for Good Reason, each of the following requirements must be met: (w) you
must provide written notice to the Board within thirty (30) days after the first occurrence of the event giving rise to Good Reason setting forth the basis for your resignation, (x) you must allow the Company at least thirty
(30) days from receipt of such written notice (the “Cure Period”) to cure such event, (y) such event is not reasonably cured by the Company within the Cure Period, and (z) you must resign from all
positions you then hold with the Company not later than sixty (60) days after the expiration of the Cure Period. 
 3.
“Release Obligation” means that: (a) you have signed a general release and waiver of claims in favor of the Company and its affiliates, as part of a termination agreement acceptable to the Company that contains
standard provisions including a nondisparagement provision and restrictive covenants to the maximum enforceable extent including without limitation a noncompetition covenant during the period you are eligible to receive Severance Payments, and
(b) you have allowed the release and waiver to become fully effective without revocation during any applicable revocation period. 
 Change
in Control 
 Upon the termination of your employment by the Company without Cause, or by you with Good Reason, in either case during a time period
starting on the date one (1) month before the closing of a Change in Control and ending on the date twelve (12) months after the closing of a Change in Control, provided that you meet the Release Obligation and you provide continued
services through your termination date, then your Options and RSUs shall vest in full (“Accelerated Vesting”), effective as of the termination date of your employment. 

A “Change in Control” shall mean any of the following: (a) a merger or consolidation in which the Company is a constituent party
(or if a subsidiary of the Company is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation), other than a merger or consolidation in which the voting securities of the Company outstanding
immediately prior to such merger or consolidation continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the combined voting power of the
voting securities of the surviving entity outstanding immediately after such merger or consolidation, or (b) any transaction or series of related transactions in which in excess of fifty percent (50%) of the Company’s voting
power is transferred, other than the sale by the Company of stock in transactions the primary purpose of which is to raise capital for the Company’s operations and activities, or (c) a sale, lease, exclusive license or other
disposition of all or substantially all (as determined by the Board in its sole discretion) of the assets of the Company. 
 Section 280G 

If any payment or benefit (including payments and benefits pursuant to this Agreement) that you would receive in connection with a Change in Control from the
Company or otherwise (“Transaction Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Internal Revenue Code (the “Code”), and (ii) but for this
sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Transaction Payment are paid to you, which of the following
two alternative forms of 

 Adam Woodrow 

February 4, 2015 
  Page
 5
 
  

 
payment would result in your receipt, on an after-tax basis, of the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject to
the Excise Tax: (1) payment in full of the entire amount of the Transaction Payment (a “Full Payment”), or (2) payment of only a part of the Transaction Payment so that you receive the largest payment possible without the
imposition of the Excise Tax (a “Reduced Payment”). For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state and local
income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced
Payment is made, (x) you shall have no rights to any additional payments and/or benefits constituting the Transaction Payment, and (y) reduction in payments and/or benefits shall occur in the manner that results in the greatest economic
benefit to you as determined in this paragraph. If more than one method of reduction will result in the same economic benefit, the portions of the Transaction Payment shall be reduced pro rata. Unless you and the Company otherwise agree
in writing, any determination required under this paragraph shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon you and the
Company for all purposes. For purposes of making the calculations required by this paragraph, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations
concerning the application of Sections 280G and 4999 of the Code. You and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this
paragraph. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this paragraph as well as any costs incurred by you with the Accountants for tax planning under Sections 280G
and 4999 of the Code. 
 Compliance with Proprietary Information Agreement and Company Policies 

As a condition of employment, you have signed and must continue to comply with the Company’s standard form of Employee Proprietary Information, Inventions
Assignment, Non-Competition and Non-Solicitation Agreement (the “Proprietary Information Agreement”, a copy of which is attached hereto as Exhibit A) which prohibits unauthorized use or disclosure of the Company’s
proprietary information, among other obligations. As a Paratek employee, you will be expected to abide by Company policies and practices, as may be changed from time to time in the Company’s discretion, and acknowledge in writing that you have
read the Company’s employee handbook. 
 Protection of Third Party Information 

In your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or
other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in
the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises, or use in the performance of your duties, any unpublished documents or
property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the
Company. 

 Adam Woodrow 

February 4, 2015 
  Page
 6
 
  

 Outside Activities 

Except with the prior written consent of the Board, you will not during your employment engage in any other employment, occupation or business enterprise,
other than ones in which you are a passive investor. You may engage in civic and not-for-profit activities so long as such activities do not materially interfere with the performance of your duties. During your employment, you agree not to acquire,
assume or participate in, directly or indirectly, any entity, investment, or interest known by you to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise, including any person, corporation, firm, partnership
or other entity whatsoever known by you to compete with the Company (or is planning or preparing to compete with the Company), anywhere in the world, in any line of business engaged in (or planned to be engaged in) by the Company. You may purchase
or otherwise acquire up to one percent (1%) of any class of securities of any enterprise if such securities are listed on any national or regional securities exchange, provided that you refrain from participating in the business activities of
such enterprise. 
 Agreement to Arbitrate 
 To ensure
the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company both agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to
statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment with the Company, will be resolved pursuant to the
Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted in Boston, Massachusetts by JAMS, Inc. (“JAMS”) or its successors. 

Both you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a
trial by jury or judge or administrative proceeding. 
 Any such arbitration proceeding will be governed by JAMS’ then applicable rules and
procedures for employment disputes, which can be found at http://www.jamsadr.com/rules-clauses/, and which will be provided to you upon request. In any such proceeding, the arbitrator shall: (i) have the authority to compel adequate
discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the
award. You and the Company each shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law. Nothing in this Agreement is intended to prevent either the Company or you from obtaining injunctive relief in
court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. 
 Entire Agreement; Contingencies 

This Agreement, together with your Proprietary Information Agreement, forms the complete and exclusive statement of your employment agreement with the Company.
It supersedes any other prior agreements or promises made to you by anyone, whether oral or written, including the Employment Agreement. Changes in your employment terms, other than those changes expressly reserved to the Company’s or
Board’s discretion in this Agreement, require a written modification approved by the Board and signed by a duly authorized Member of the Board. 
 This
Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined
to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of
the parties insofar as possible under applicable law. 

 Adam Woodrow 

February 4, 2015 
  Page
 7
 
  

 This Agreement shall be construed and enforced in accordance with the laws of the Commonwealth of
Massachusetts without regard to conflicts of law principles. Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. This Agreement may
be executed in counterparts which shall be deemed to be part of one original, and pdf or other facsimile signatures shall be equivalent to original signatures. 

[remainder of page intentionally left blank] 

 Adam Woodrow 

February 4, 2015 
  Page
 8
 
  

 Please sign and date this Agreement to indicate your acceptance of continued employment at Paratek under the
terms described above. We look forward to a continued productive and enjoyable work relationship. 
  

	
	Sincerely,
	
	Paratek Pharmaceuticals, Inc.
	
	 /s/ MICHAEL F. BIGHAM

	Michael F. Bigham
	Chairman of the Board and Chief Executive Officer
	
	Accepted:
	
	 /s/ ADAM WOODROW

	Adam Woodrow
	
	 February 25, 2015

	Date

 Adam Woodrow 

February 4, 2015 
  Page
 9
 
  

 Exhibit A 

EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT, NON-COMPETITION 

AND NON-SOLICITATION AGREEMENT 

 Exhibit A 

EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT, NON-COMPETITION 

AND NON-SOLICITATION AGREEMENT 

In consideration of my employment or continued employment by Paratek Pharmaceuticals, Inc., its subsidiaries, parents, affiliates,
successors and assigns (together, the “Company”) and the compensation now and hereafter paid to me, I hereby enter into this Employee Proprietary Information, Inventions Assignment, Non-Competition and Non-Solicitation Agreement
(the “Agreement”) and agree as follows: 

 

 1. NONDISCLOSURE. 

1.1 Recognition of Company’s Rights; Nondisclosure. I understand and acknowledge that my employment by the Company creates a
relationship of confidence and trust with respect to the Company’s Proprietary Information (defined below) and that the Company has a protectable interest therein. At all times during my employment and thereafter, I will hold in strictest
confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information, except as such disclosure, use or publication may be required in connection with my work for the Company, or unless an authorized
officer of the Company expressly authorizes such in writing. I will obtain the Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that relates to my work at the Company and/or
incorporates any Proprietary Information. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole property of the Company and its assigns. I
will take all reasonable precautions to prevent the inadvertent or accidental disclosure of Proprietary Information. 
 1.2 Proprietary
Information. The term “Proprietary Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company, its affiliates, parents and subsidiaries, whether having existed, now
existing, or to be developed during my employment. By way of illustration but not limitation, “Proprietary Information” includes (a) trade secrets, inventions, ideas, processes, formulas, assay components, biological materials,
cell lines, and clinical data, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Proprietary Rights therein (hereinafter collectively
referred to as “Inventions”); (b) information regarding research, development, new products, marketing and selling,

 
business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining
business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of
conducting Company business, suppliers and supplier information, and purchasing; (c) information regarding customers and potential customers of the Company, including customer lists, names, representatives, their needs or desires with respect
to the types of products or services offered by the Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of the
Company and other non-public information relating to customers and potential customers; (d) information regarding any of the Company’s business partners and their services, including names; representatives, proposals, bids, contracts and
their contents and parties, the type and quantity of products and services received by the Company, and other non-public information relating to business partners; (e) information regarding personnel, employee lists, compensation, and employee
skills; and (f) any other non-public information which a competitor of the Company could use to the competitive disadvantage of the Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information
which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me, and I am free to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7
of the National Labor Relations Act. 
 1.3 Third Party Information. I understand, in addition, that the Company has received and
in the future will receive confidential and/or proprietary knowledge, data, or information from third parties (“Third Party Information”).

 

 
During my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such
information in connection with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an authorized officer of the Company in writing. 

1.4 Term of Nondisclosure Restrictions. I understand that Proprietary Information and Third Party Information is never to be used or
disclosed by me, as provided in this Section 1. If, however, a court decides that this Section 1 or any of its provisions is unenforceable for lack of reasonable temporal limitation and the Agreement or its restriction(s) cannot otherwise
be enforced, I agree and the Company agrees that the two (2) year period after the date my employment ends shall be the temporal limitation relevant to the contested restriction, provided, however, that this sentence shall not apply to trade
secrets protected without temporal limitation under applicable law. 
 1.5 No Improper Use of Information of Prior Employers and
Others. During my employment by the Company I will not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not
bring onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.

 2. ASSIGNMENT OF INVENTIONS. 

2.1 Proprietary Rights. The term “Proprietary Rights” shall mean all trade secrets, patents, copyrights, trade marks
and other intellectual property rights throughout the world. 
 2.2 Prior Inventions. Inventions, if any, patented or unpatented,
which I made prior to the commencement of my employment with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on Exhibit 1 (Prior Inventions) attached hereto a complete
list of all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my employment with the Company, that I consider to
be my property or the

 
property of third parties, and that I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”). If disclosure of any such Prior
Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit 1 but am only to disclose a cursory name for each such invention, a listing of the party(ies) to
whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. A space is provided on Exhibit 1 for such purpose. If no such disclosure is attached, I represent that there are no Prior Inventions.
If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, fully-paid, worldwide
license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, make derivative works of, publicly perform, use, sell, import, and exercise any and all present and future rights in such Prior Invention.
Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions without the Company’s prior written consent. 

2.3 Assignment of Inventions. Subject to Subsection 2.4, I hereby assign, grant and convey to the Company all my right, title and
interest in and to any and all Inventions (and all Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or
jointly with others, during the period of my employment with the Company. Inventions assigned to the Company or its designee are hereinafter referred to as “Company Inventions.” 

2.4 Unassigned or Nonassignable Inventions. I recognize that this Agreement will not be deemed to require assignment of any Invention
that I developed entirely on my own time without using the Company’s equipment, supplies, facilities, trade secrets, or Proprietary Information, except for those Inventions that either (i) relate to the Company’s actual or anticipated
business, research or development, or (ii) result from or are connected with work performed by me for the Company. In addition, this Agreement does not apply to any Invention which qualifies fully for protection from assignment to the Company
under any specifically applicable state law, regulation, rule, or public policy (“Specific Inventions Law”). 

 

  
 A-2 

 
 2.5 Obligation to Keep Company Informed. During the period of my employment and for six
(6) months after termination of my employment with the Company, I will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced to practice by me, either alone or jointly with others. In addition, I
will promptly disclose to the Company all patent applications filed by me or on my behalf within a year after termination of employment. At the time of each such disclosure, I will advise the Company in writing of any Inventions that I believe fully
qualify for protection under the provisions of a Specific Inventions Law; and I will at that time provide to the Company in writing all evidence necessary to substantiate that belief. The Company will keep in confidence and will not use for any
purpose or disclose to third parties without my consent any confidential information disclosed in writing to the Company pursuant to this Agreement relating to Inventions that qualify fully for protection under a Specific Inventions Law. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under a Specific Inventions Law. 
 2.6
Ownership of Work Product. I agree that the Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I hereby irrevocably and unconditionally assign to the Company
all right, title, and interest worldwide in and to such work product. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by copyright
are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101). I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by
this Section, except as necessary to perform services for the Company. 
 2.7 Enforcement of Proprietary Rights. I will assist the
Company in every proper way to obtain, and from time to time enforce, United States and foreign Proprietary Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform
such other acts (including appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will
execute, verify and deliver assignments of such Proprietary Rights to the Company or its designee, including the

 
United States or any third party designated by the Company. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries
shall continue beyond the termination of my employment, but the Company shall compensate me at a reasonable rate after my termination for the time actually spent by me at the Company’s request on such assistance. 

In the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions
specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to
execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and
all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Proprietary Rights assigned under this Agreement to the Company. 

3. RECORDS. I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form
that may be required by the Company) of all Proprietary Information developed by me and all Inventions made by me during the period of my employment at the Company, which records shall be available to and remain the sole property of the Company at
all times. 
 4. DUTY OF LOYALTY DURING EMPLOYMENT. I agree that during
the period of my employment by the Company I will not, without the Company’s express written consent, directly or indirectly engage in any employment or business activity which is directly or indirectly competitive with, or would otherwise
conflict with, my employment by the Company. 
 5. NO SOLICITATION OF EMPLOYEES,
CONSULTANTS, CONTRACTORS, OR CUSTOMERS OR POTENTIAL CUSTOMERS. I agree that during the period of my employment and for the one (1) year
period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by the Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other
capacity, either directly or through others, except on behalf of the Company: 
 5.1 solicit, induce, encourage, or participate in
soliciting, inducing, or encouraging any employee of the Company to terminate his or her relationship with the Company; 

 

  
 A-3 

 
 5.2 hire, employ, or engage in business with or attempt to hire, employ, or engage in
business with any person employed by the Company or who has left the employment of the Company within the preceding three (3) months of any such prohibited activity or discuss any potential employment or business association with such person,
even if I did not initiate the discussion or seek out the contact; 
 5.3 solicit, induce or attempt to induce any Customer or
Potential Customer, or any consultant or independent contractor with whom I had direct or indirect contact during my employment with the Company or whose identity I learned as a result of my employment with the Company, to terminate, diminish, or
materially alter in a manner harmful to the Company its relationship with the Company; or 
 5.4 solicit, perform, provide or
attempt to perform or provide any Conflicting Services (as defined in Section 6 below) for a Customer or Potential Customer. 
 The parties agree that
for purposes of this Agreement, a “Customer or Potential Customer” is any person or entity who or which, at any time during the one (1) year prior to the date my employment with the Company ends, (i) contracted for,
was billed for, or received from the Company any product, service or process with which I worked directly or indirectly during my employment by the Company or about which I acquired Proprietary Information; or (ii) was in contact with me or in
contact with any other employee, owner, or agent of the Company, of which contact I was or should have been aware, concerning any product, service or process with which I worked directly or indirectly during my employment with the Company or about
which I acquired Proprietary Information; or (iii) was solicited by the Company in an effort in which I was involved or of which I was or should have been aware. 

6. NON-COMPETE PROVISION. I agree that for the one (1) year period after the date my employment ends
for any reason, including but not limited to voluntary termination by me or involuntary termination by the Company, I will not, directly or indirectly, as an officer, director, employee,

 
consultant, owner, manager, member, partner, or in any other capacity solicit, perform, or provide, or attempt to perform or provide Conflicting Services anywhere in the world where the Company
conducts business, including but not limited to locations where the Company performs research or development activities related to the Company’s products, services or processes (such locations the “Restricted
Territory”), nor will I assist another person to solicit, perform or provide or attempt to perform or provide Conflicting Services in the Restricted Territory. 

The parties agree that for purposes of this Agreement, “Conflicting Services” means any product, service, or process or the research
and development thereof, of any person or organization other than the Company that has antibiotics as its principal business, unless otherwise expressly excluded from this definition in advance by the Company’s Board of Directors. 

7. REASONABLENESS OF RESTRICTIONS. 

7.1 I agree that I have read this entire Agreement and understand it. I agree that this Agreement does not prevent me from earning a
living or pursuing my career and that I have the ability to secure other non-competitive employment using my marketable skills. I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by the Company’s
legitimate business interests, including without limitation, the Company’s Proprietary Rights, Proprietary Information and the goodwill of its customers. I represent and agree that I am entering into this Agreement freely and with knowledge of
its contents with the intent to be bound by the Agreement and the restrictions contained in it. 
 7.2 In the event that a court
finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, the Company and I agree that the court shall read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the
maximum extent allowed by law. 
 7.3 If the court declines to enforce this Agreement in the manner provided in subsection 7.2, I
and the Company agree that this Agreement will be automatically modified to provide the Company with the maximum protection of its business interests allowed by law and I agree to be bound by this Agreement as modified.

 

  
 A-4 

 
 8. NO CONFLICTING AGREEMENT OR
OBLIGATION. I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement or obligation of any kind to keep in confidence information acquired by me
in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement. 

9. RETURN OF COMPANY PROPERTY. Upon termination of my employment or upon Company’s
request at any other time, I will deliver to Company all of Company’s property, equipment, and documents, together with all copies thereof, and any other material containing or disclosing any Inventions, Third Party Information or Proprietary
Information and certify in writing that I have fully complied with the foregoing obligation. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company. In
addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Proprietary Information, I agree to provide the Company with a
computer-useable copy of all such Proprietary Information and then permanently delete and expunge such Proprietary Information from those systems; and I agree to provide the Company access to my system as reasonably requested to verify that the
necessary copying and/or deletion is completed. I further agree that any property situated on Company’s premises and owned by Company is subject to inspection by Company’s personnel at any time with or without notice. Prior to the
termination of my employment or promptly after termination of my employment, I will cooperate with Company in attending an exit interview and certify in writing that I have complied with the requirements of this section. 

10. LEGAL AND EQUITABLE REMEDIES. 

10.1 I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree
that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to the Company and the Company shall have the right to enforce this Agreement and any of its provisions by injunction,
specific performance or other equitable relief, without bond and without prejudice to any other rights and

 
remedies that the Company may have for a breach or threatened breach of this Agreement. 

10.2 I agree that if the Company is successful in whole or in part in any legal or equitable action against me under this Agreement,
the Company shall be entitled to payment of all costs, including reasonable attorney’s fees, from me. 
 10.3 In the event the
Company enforces this Agreement through a court order, I agree that the restrictions of Sections 5 and 6 shall remain in effect for a period of twelve (12) months from the effective date of the Order enforcing the Agreement. 

11. NOTICES. Any notices required or permitted under this Agreement will be given to the Company at its headquarters location at the
time notice is given, labeled “Attention Chief Executive Officer,” and to me at my address as listed on the Company payroll, or at such other address as the Company or I may designate by written notice to the other. Notice will be
effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or
express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt. 
 12.
PUBLICATION OF THIS AGREEMENT TO SUBSEQUENT EMPLOYERS OR BUSINESS ASSOCIATES OF EMPLOYEE. 
 12.1 If I am offered employment or
the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the restrictions described in Sections 5 and 6 of this Agreement are in effect I agree to inform my potential employer, partner, co-owner and/or
others involved in managing the business with which I have an opportunity to be associated of my obligations under this Agreement and also agree to provide such person or persons with a copy of this Agreement. 

12.2 I agree to inform the Company of all employment and business ventures which I enter into while the restrictions described in
Sections 5 and 6 of this Agreement are in effect and I also authorize the Company to provide copies of this Agreement to my employer, partner, co-owner and/or others involved in managing the business with which I am employed or associated and to
make such persons aware of my obligations under this Agreement. 

 

  
 A-5 

 
 13. GENERAL PROVISIONS. 

13.1 Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by and construed according to the laws of the
Commonwealth of Massachusetts as such laws are applied to agreements entered into and to be performed entirely within the Commonwealth of Massachusetts between Massachusetts residents. I hereby expressly consent to the personal jurisdiction and
venue of the state and federal courts located in the Commonwealth of Massachusetts for any lawsuit filed there against me by Company arising from or related to this Agreement. 

13.2 Severability. In case any one or more of the provisions, subsections, or sentences contained in this Agreement shall, for any
reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or
subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. 

13.3 Successors and Assigns. This Agreement is for my benefit and the benefit of the Company, its successors, assigns, parent
corporations, subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives. 

13.4 Survival. The provisions of this Agreement shall survive the termination of my employment, regardless of the reason, and the
assignment of this Agreement by the Company to any successor in interest or other assignee. I understand that my obligations under this Agreement will continue in accordance with its express terms regardless of any change in my title, position,
status, role, duties, salary, compensation or benefits or other terms and conditions of employment or service. 
 13.5 Employment
At-Will. I agree and understand that nothing in this Agreement shall

 
change my at-will employment status or confer any right with respect to continuation of employment by the Company, nor shall it interfere in any way with my right or the Company’s right to
terminate my employment at any time, with or without cause or advance notice. 
 13.6 Waiver. No waiver by the Company of any
breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by the Company of any right under this Agreement shall be construed as a waiver of any other right. The Company shall not be required to give notice to
enforce strict adherence to all terms of this Agreement. 
 13.7 Advice of Counsel. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I
HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR
PREPARATION OF THIS AGREEMENT. 
 13.8 Entire Agreement. The obligations pursuant to Sections 1 and 2 (except Subsection 2.6)
of this Agreement shall apply to any time during which I was previously engaged, or am in the future engaged, by the Company as a consultant if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement
is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any
rights under this Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my title, position, status, role, duties, salary, compensation or benefits or other terms and conditions of
employment or service will not affect the validity or scope of this Agreement. 

 

  
 A-6 

 This Agreement shall be effective as of the first day of my employment with the Company. 

 

									
	ADAM WOODROW:				PARATEK PHARMACEUTICALS, INC.
			
	I HAVE READ, UNDERSTAND, AND ACCEPT THIS AGREEMENT AND HAVE BEEN
GIVEN THE OPPORTUNITY TO REVIEW IT WITH INDEPENDENT LEGAL COUNSEL.				ACCEPTED AND AGREED:
			
	 /s/ Adam Woodrow
				 /s/ Michael F. Bigham

	(Signature)				(Signature)
					
	Date:		February 25, 2015				By:		Michael F. Bigham
					
	Address:		1675 Stephens Drive, Wayne, PA 19087				Title:		Chairman & Chief Executive Officer
					
							Date:		February 25, 2015
					
							Address:		75 Kneeland Street, Boston, Massachusetts 02111

 EXHIBIT 1 

PRIOR INVENTIONS 
  

					
	TO:	  	Paratek Pharmaceuticals, Inc.	  	
			
	FROM:	  	Adam Woodrow	  	
			
	DATE:	  	  
	  	
			
	SUBJECT:	  	Prior Inventions	  	

 1. Except as listed in Section 2 below, the following is a complete list of all inventions or improvements
relevant to the subject matter of my employment by Paratek Pharmaceuticals, Inc. (the “Company”) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the
Company: 
  

			
	 ̈	  	No inventions or improvements.
		
	 ̈	  	See below:
		
		  	  

		
		  	  

		
		  	  

  

	 ̈	Additional sheets attached. 

 2. Due to a prior confidentiality agreement, I cannot complete the
disclosure under Section 1 above with respect to inventions or improvements generally listed below, the proprietary rights and duty of confidentiality with respect to which I owe to the following party(ies): 

 

							
	 	  	Invention or Improvement	  	Party(ies)	  	Relationship
				
	1.	  	  
	  	  
	  	  

				
	2.	  	  
	  	  
	  	  

				
	3.	  	  
	  	  
	  	  

  

	 ̈	Additional sheets attached. 

  
 A-8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]